SCHEMBL671710

SCHEMBL671710

CCCn1cc(B(O)O)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
PIK3CD O00329 1/20 0.35
PIP5K1C O60331 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PI4KA P42356 1/20 0.35
PIK3CG P48736 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
LPL P06858 6/20 0.34
LIPG Q9Y5X9 6/20 0.34
NAMPT P43490 4/20 0.34
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
KDM5B Q9UGL1 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23227826 0.89 L3MBTL1 (0.41) L3MBTL1LPLLIPGALDH1A1CA1
SCHEMBL532133 0.84 KMT2A (0.38) L3MBTL1PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL2551385 0.82 KIT (0.37) L3MBTL1NAMPTPRMT5WDR77KDM5B
SCHEMBL15334490 0.81 L3MBTL1 (0.33) L3MBTL1
SCHEMBL23227824 0.81 MAPT (0.33) L3MBTL1MAPT
SCHEMBL1128873 0.80 NAMPT (0.41) L3MBTL1NAMPTALDH1A1PRMT5WDR77
SCHEMBL15330710 0.80 IKBKE (0.36) L3MBTL1KDM5B
SCHEMBL15330085 0.80 BRD4 (0.34) L3MBTL1PIK3CA
SCHEMBL2555665 0.78 JAK2 (0.35) L3MBTL1POLB
SCHEMBL15331282 0.78 MAP3K5 (0.36) L3MBTL1NAMPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737443-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Pharma Corporation (JP) 2026-05-06 EP disclosed
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-03-05 US disclosed
WO-2024242169-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 田辺三菱製薬株式会社 2024-11-28 WO disclosed
CN-117946018-A S-triazine LSD1 inhibitor and preparation method and application thereof 郑州大学 2024-04-30 CN disclosed
WO-2023205173-A1 SUBSTITUTED PIPERIDINES AND SUBSTITUTED TETRAHYDROPYRIDINES AS IMMUNE-MODULATING COMPOUNDS BLACKSMITH MEDICINES, INC. (US) 2023-10-26 WO disclosed
WO-2023205173-A1 SUBSTITUTED PIPERIDINES AND SUBSTITUTED TETRAHYDROPYRIDINES AS IMMUNE-MODULATING COMPOUNDS BLACKSMITH MEDICINES, INC. (US) 2023-10-26 WO disclosed
US-20230063230-A1 NURR1 RECEPTOR MODULATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-02 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-4073054-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS Fondazione Istituto Italiano di Tecnologia (IT) 2022-10-19 EP disclosed
US-20220227751-A1 NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. GALAPAGOS NV (BE) 2022-07-21 US disclosed
WO-2010141406-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2010-12-09 WO disclosed
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-11-25 US disclosed
EP-2217578-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2010-08-18 EP disclosed
US-20100009962-A1 Benzyl-substituted quinolone m1 receptor positive allosteric modulators MERCK SHARP & DOHME LLC 2010-01-14 US disclosed
US-20100009962-A1 Benzyl-substituted quinolone m1 receptor positive allosteric modulators MERCK SHARP & DOHME LLC 2010-01-14 US disclosed
WO-2009047514-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-16 WO disclosed
WO-2008002621-A2 BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK & CO., INC. (US) 2008-01-03 WO disclosed
US-20070072904-A1 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders PLEXXIKON INC 2007-03-29 US disclosed
US-20070072904-A1 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders PLEXXIKON INC 2007-03-29 US disclosed
WO-2007030559-A2 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS PLEXXIKON, INC. (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072904-A1 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders PPARG, PPARA, PPARD L3MBTL1 3469/4885PIK3CD 1360/4885PIP5K1C 1294/4885
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME SIK1, SIK3, SIK2 L3MBTL1 3282/4885PIK3CD 342/4885PIP5K1C 171/4885
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 L3MBTL1 1824/4885PIK3CD 261/4885PIP5K1C 627/4885
US-20230063230-A1 NURR1 RECEPTOR MODULATORS NR2E3, NR4A2, NR0B1 L3MBTL1 1113/4885PIK3CD 4071/4885PIP5K1C 4395/4885
US-20220227751-A1 NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. GPR84, GPR88, GPR65 L3MBTL1 4455/4885PIK3CD 2616/4885PIP5K1C 1793/4885
US-20100009962-A1 Benzyl-substituted quinolone m1 receptor positive allosteric modulators CHRM1, OPRL1, MTNR1A L3MBTL1 2613/4885PIK3CD 882/4885PIP5K1C 1160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.